Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven reported a Q1 2026 net loss of $130.5 million, or $0.88 per share, with R&D expenses decreasing to $103.8 million due to strategic reprioritization. The company ended the quarter with $351.8 million in cash and equivalents, supporting its development pipeline. Operational highlights include completed enrollment in the Phase 2 obesity study for taldefgrobep alfa and expected mid-year initiations of pivotal trials for BHV-1400 in IgA nephropathy and BHV-1300 in Graves' disease.
Key figures
- Net loss
- 130500000
- Ga expenses
- 26600000
- Rd expenses
- 103800000
- Cash position
- 351800000
- Non gaap net loss
- 102200000
- Shares outstanding
- 147615197
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.